Mark Densel
Corporate Officer/Principal at EFFECTOR THERAPEUTICS, INC.
Profile
Mark Densel is currently working as the Vice President-Development Operations at eFFECTOR Therapeutics, Inc. Previously, he held the position of Senior Director-Project Management at Ardea Biosciences, Inc. and Vice President-Project Management at La Jolla Pharmaceutical Co. Mr. Densel completed his undergraduate degree at Ball State University (Indiana).
Mark Densel active positions
Companies | Position | Start |
---|---|---|
EFFECTOR THERAPEUTICS, INC. | Corporate Officer/Principal | 2018-10-31 |
Former positions of Mark Densel
Companies | Position | End |
---|---|---|
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Corporate Officer/Principal | - |
LA JOLLA PHARMACEUTICAL COMPANY | Corporate Officer/Principal | - |
Training of Mark Densel
Ball State University (Indiana) | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
EFFECTOR THERAPEUTICS, INC. | Health Technology |
Private companies | 2 |
---|---|
La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |
- Stock Market
- Insiders
- Mark Densel